A systematic review and meta-analysis of mortality in anal cancer patients by HIV status

2022 ◽  
Vol 76 ◽  
pp. 102069
Author(s):  
Louise Sumner ◽  
Emiko Kamitani ◽  
Sharon Chase ◽  
Ying Wang
2020 ◽  
Author(s):  
Abhijeet Ashok Salunke ◽  
Kunal Nandy ◽  
Subodh Kumar Pathak ◽  
Ketul Puj ◽  
Vikas Warikoo ◽  
...  

Author(s):  
Ting Yang ◽  
Shurui Wang ◽  
Ruirui Wang ◽  
Yuqi Wei ◽  
Yannan Kang ◽  
...  

2017 ◽  
Vol 31 (4) ◽  
pp. 519-532 ◽  
Author(s):  
Kyeore Bae ◽  
Ji-hye Park ◽  
Jeehye Kim ◽  
Chong-kwan Cho ◽  
Byeongsang Oh ◽  
...  

BMJ Open ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. e033461
Author(s):  
Kyeore Bae ◽  
Si Yeon Song

IntroductionAromatase inhibitor-induced arthralgia (AIA) is a major adverse event of aromatase inhibitors (AIs) and leads to premature discontinuation of AI therapy in breast cancer patients. The objective of this protocol for a systematic review and network meta-analysis (NMA) is to provide the methodology to compare the change in pain intensity between different AIA treatments and demonstrate the rank probabilities for different treatments by combining all available direct and indirect evidence.Methods and analysisPubMed, the Cochrane Controlled Register of Trials (CENTRAL), EMBASE, Web of Science and ClinicalTrials.gov will be searched to identify publications in English from inception to November 2019. We will include randomised controlled trials (RCTs) assessing the effects of different treatments for AIA in postmenopausal women with stage 0–III hormone receptor-positive breast cancer. The primary endpoints will be the change in patient-reported pain intensity from baseline to post-treatment. The number of adverse events will be presented as a secondary outcome.Both pairwise meta-analysis and NMA with the Frequentist approach will be conducted. We will demonstrate summary estimates with forest plots in meta-analysis and direct and mixed evidence with a ranking of the treatments as the P-score in NMA. The revised Cochrane risk-of-bias tool for randomised trials will be used to assess the methodological quality within individual RCTs. The quality of evidence will be assessed.Ethics and disseminationAs this review does not involve individual patients, ethical approval is not required. The results of this systematic review and NMA will be published in a peer-reviewed journal. This review will provide valuable information on AIA therapeutic options for clinicians, health practitioners and breast cancer survivors.PROSPERO registration numberCRD42019136967.


Sign in / Sign up

Export Citation Format

Share Document